Szczepionki nowej generacji

• Autorzy: Truszczynski M , Pejsak Z.

Warianty tytułu

EN

New generation vaccines

• Języki publikacji: PL

Abstrakty

EN

The study characterized inactivated subunit vaccines; DNA vaccines; live, attenuated, gene-deleted vaccines; live recombinant vector vaccines and marker vaccines. This group of new generation vaccines, developed by the use of genetic engineering, was compared with conventional vaccines, based on microbiologic techniques. It was shown that vaccines based on modern technology extend the possibilities of immunoprophylaxis and control of infectious diseases in animals. They contribute to lowering the frequency of post-vaccination complications. Simultaneously, they provide higher efficacy and long-term protective immunity, due to the presence of protective antigens without immunity inhibiting factors as well as modern adjuvants (e.g. ISCOM). Marker vaccines provide the basis for serologically differentiating vaccinated animals from infected animals and from vaccinated and simultaneously infected animals, which has been defined as DIVA strategy. This approach facilitates partial replacement of the stamping-out method of animals during outbreaks of the disease both within their epicenter and perimeters thereby reducing losses caused by dangerous epizootic diseases such as foot and mouth disease, classical swine fever, Aujeszkys disease and avian influenza.

Słowa kluczowe

PL

szczepionki delecyjne; szczepionki DNA; szczepionki nowej generacji; szczepionki wektorowe rekombinowane; szczepionki delecyjne atenuowane; szczepionki podjednostkowe inaktywowane; szczepionki znakowane; szczepionki wektorowe; biotechnologia; szczepionki

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2006
• Tom: 62
• Numer: 08
• Opis fizyczny: s.855-859,bibliogr.

Twórcy

autor

Truszczynski M

• Panstwowy Instytut Weterynaryjny - Panstwowy Instytut Badawczy, Al.Partyzantow 57, 24-100 Pulawy

autor

Pejsak Z.

Bibliografia

• 1.Babiuk L. A., Tikoo S. K.: Adenovirus as vector for delivering vaccines to mucosal surfaces. J. Biotechnol. 2000, 83, 105-113.
• 2.Babiuk L. A.: Broadening the approaches to developing more effective vaccines. Vaccine 1999, 17, 1587-1595.
• 3.Brochier B., Costy F., Pastoret P. P.: Elimination of fox rabies from Belgium using a recombinant vaccinia-rabies vaccine: an update. Vet. Microbiol. 1995, 46, 269-279.
• 4.Brochier B., Kieny M. P., Costy F., Coppenes P., Bauduin B., Lecocq J. P., Languet B., Chappuis G., Desmettre P., Afiademanyo K.: Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine. Nature 1991, 354, 520-522.
• 5.Capua I., Marangon S.: Vaccination for avian influenza in Asia. Vaccine 2004, 22, 4137-4138.
• 6.Commission Decision 2000/721/EC of 7 November 2000 on introducing vaccination to supplement the measures to control avian influenza in Italy and on specific movement control measures. Off. J. Eur. Comm. 2000, L 291, 33-36.
• 7.Council Directive 92/40/EEC of 19 May 1992 introducing Community measures for the control of avian influenza. Off. J. Eur. Comm. 1992, L 167, 1-16.
• 8.Drabner B., Guzman C.: Elicitation of predictable immune responses by using live bacterial vectors. Biomol. Eng. 2001, 17, 75-82.
• 9.Giambrone J.: Development of transgenic edible plant vaccines against bursal disease viruses and reoviruses. 14th World Veterinary Poulty Congress, Istambul, Turkey 2005, Abstract No 099-25.
• 10.Grzesiowski P., Hryniewicz W., red. Gołąb J., Jakóbisiak M., Lasek W.: Immunologia. PWN, Warszawa 2002.
• 11.Hu Y. C., Bentley W. E.: Enhancing yield of infectious bursal disease structural proteins in baculovirus expression systems: focus on media, protease inhibitors and dissolved oxygen. Biotechnology Prog. 1999, 15, 1065-1071.
• 12.Kit S., Sheppard M., Ichimura H., Kit M.: Second generation pseudorabies virus vasccine with deletions in thymidine kinase and glycoprotein genes. Am. J. vet. Res. 1987, 48, 780-793.
• 13.Koprowski H.: Vaccines and sera through plant biotechnology. Vaccine 2005, 23, 1757-1763.
• 14.Kowalski J., Gilbert S. A., van Drunen Little-van den Hurk S., van den Hurk J., Babiuk L. A., Zamb T.: Heat-shock promoter-driven synthesis of secreted bovine herpesvirus glycoproteins in transfected cells. Vaccine 1993, 11, 1100- -1108.
• 15.Legocki A. B., Miedzinska K., Czapliñska M., P³ucieniczak A., Wêdrychowicz H.: Immunoprotective properties of transgenic plants expressing E2 glycoprotein from CSFV and cysteine protease from Fasciola hepatica. Vaccine 2005, 23, 1844-1846.
• 16.Liljeqvist S., Stahl S.: Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines. J. Biotechnol. 1999, 73, 1-33.
• 17.Marciani D. J., Kensil C. R., Beltz G. A., Hung C. H., Cronier J., Aubert A.: Genetically-engineered subunit vaccine against feline leukemia virus: protective immune response in cats. Vaccine 1991, 2, 89-96.
• 18.Martin-Gallardo A., Fleischer E., Doyle S. A., Arumugham R., Collins P. L., Hildreth S. W., Paradiso P. R.: Expression of the G glycoprotein gene of human respiratory syncytial virus in Salmonella typhimurium. J. gen. Virol. 1993, 74, 453-458.
• 19.Mengeling W. L., Brockmeier S. L., Lager K. M., Vorwald A. C.: The role of biotechnologically engineered vaccines and diagnostics in pseudorabies (Aujeszky’s disease) eradication strategies. Vet. Microbiol. 1997, 55, 49-60.
• 20.Moss B., Flexner C.: Vaccinia virus expression vectors. Annu. Rev. Immunol. 1987, 5, 305-324.
• 21.Murby M., Samuelsson E., Nguyen T. N., Mignard L., Power U., Binz H., Uhlen M., Stahl S.: Hydrophobicity engineering to increase solubility and stability of a recombinant protein from respiratory syncytial virus. Eur. J. Biochem. 1995, 230, 38-44.
• 22.Pastoret P. P., Blancou J., Vannier P., Verschueren red.: Veterinary Vaccinology. Elsevier, Amsterdam 1997.
• 23.Rogan D., Babiuk L. A.: Novel vaccines from biotechnology. Rev. sci. tech. Off. int. Epiz. 2005, 24, 159-174.
• 24.Ruitenberg K. M., Gilkerson J. R., Wellington J. E., Love D. N., Whalley J. M.: Equine herpesvirus 1 glycoprotein D expressed in Pichia pastoris is hyperglycosylated and elicits a protective immune response in the mouse model of EHV-1 disease. Virus Res. 2001, 79, 125-135.
• 25.Sheppard M.: Viral vectors for veterinary vaccines. Adv. Vet. Med. 1999, 41, 145-161.
• 26.Truszczyñski M.: 70. Sesja Generalna OIE, ze szczególnym uwzględnieniem problematyki naukowej. Medycyna Wet. 2002, 58, 815-818.
• 27.Van der Leek M. L., Feller J. A., Sorensen G., Isaacson W., Adams C., Borde D., Pfeiffer N., Tran T., Moyer R., Gibbs E.: Evaluation of swine pox virus as a vaccine vector in pigs using an Aujeszky’s disease (pseudorabies) virus gene insert coding for glycoproteins gp 50 and gp 63. Vet. Rec. 1994, 134, 13-18.
• 28.Van Oirschot J.: Diva vaccines that reduce virus transmission. J. Biotechnol. 1999, 73, 195-205.
• 29.Zakhartchouk A. N., Reedy P. S., Baxi M. K., Baca-Estrada M. E., Mechtali M., Babiuk L. A., Tikoo S. K.: Construction and characterization of E3 deleted bovine adenovirus type 3 expressing full lenghth and truncated from of bovine herpes virus glycoprotein D. Virology 1998, 250, 220-229.